Opus Genetics Statistics
Total Valuation
Opus Genetics has a market cap or net worth of $123.57 million. The enterprise value is $92.14 million.
Important Dates
The next estimated earnings date is Tuesday, November 11, 2025, before market open.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Opus Genetics has 63.05 million shares outstanding. The number of shares has increased by 62.36% in one year.
| Current Share Class | 63.05M |
| Shares Outstanding | 63.05M |
| Shares Change (YoY) | +62.36% |
| Shares Change (QoQ) | +87.03% |
| Owned by Insiders (%) | 15.77% |
| Owned by Institutions (%) | 30.68% |
| Float | 29.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.89 |
| Forward PS | 9.86 |
| PB Ratio | 6.72 |
| P/TBV Ratio | 7.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.90, with a Debt / Equity ratio of 0.06.
| Current Ratio | 1.90 |
| Quick Ratio | 1.83 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -200.57% and return on invested capital (ROIC) is -77.98%.
| Return on Equity (ROE) | -200.57% |
| Return on Assets (ROA) | -55.20% |
| Return on Invested Capital (ROIC) | -77.98% |
| Return on Capital Employed (ROCE) | -199.60% |
| Revenue Per Employee | $856,722 |
| Profits Per Employee | -$3.24M |
| Employee Count | 18 |
| Asset Turnover | 0.37 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +54.33% in the last 52 weeks. The beta is 0.37, so Opus Genetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | +54.33% |
| 50-Day Moving Average | 1.41 |
| 200-Day Moving Average | 1.13 |
| Relative Strength Index (RSI) | 68.74 |
| Average Volume (20 Days) | 445,129 |
Short Selling Information
The latest short interest is 125,683, so 0.20% of the outstanding shares have been sold short.
| Short Interest | 125,683 |
| Short Previous Month | 90,128 |
| Short % of Shares Out | 0.20% |
| Short % of Float | 0.43% |
| Short Ratio (days to cover) | 0.34 |
Income Statement
In the last 12 months, Opus Genetics had revenue of $15.42 million and -$58.28 million in losses. Loss per share was -$1.51.
| Revenue | 15.42M |
| Gross Profit | -14.57M |
| Operating Income | -36.87M |
| Pretax Income | -58.28M |
| Net Income | -58.28M |
| EBITDA | -36.84M |
| EBIT | -36.87M |
| Loss Per Share | -$1.51 |
Full Income StatementBalance Sheet
The company has $32.43 million in cash and $1.00 million in debt, giving a net cash position of $31.43 million or $0.50 per share.
| Cash & Cash Equivalents | 32.43M |
| Total Debt | 1.00M |
| Net Cash | 31.43M |
| Net Cash Per Share | $0.50 |
| Equity (Book Value) | 17.47M |
| Book Value Per Share | 0.29 |
| Working Capital | 18.25M |
Full Balance SheetCash Flow
| Operating Cash Flow | -31.83M |
| Capital Expenditures | n/a |
| Free Cash Flow | -31.83M |
| FCF Per Share | -$0.50 |
Full Cash Flow StatementMargins
| Gross Margin | -94.48% |
| Operating Margin | -239.11% |
| Pretax Margin | -377.89% |
| Profit Margin | n/a |
| EBITDA Margin | -238.89% |
| EBIT Margin | -239.11% |
| FCF Margin | n/a |
Dividends & Yields
Opus Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -62.36% |
| Shareholder Yield | -62.36% |
| Earnings Yield | -47.16% |
| FCF Yield | -25.76% |
Analyst Forecast
The average price target for Opus Genetics is $6.33, which is 222.96% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.33 |
| Price Target Difference | 222.96% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 29.33% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Opus Genetics has an Altman Z-Score of -6.64 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.64 |
| Piotroski F-Score | 1 |
